FDA action counts
| Total FDA actions | 2 |
|---|---|
| Warning letters | 0 |
| Recalls | 0 |
| Approval records | 2 |
| Form 483 inspection citations | 0 |
| Most recent action | June 25, 2026 |
Enforcement history
On 2026-06-25, Argus HQ recorded a FDA approval for MYLAN, rated "info" severity in Argus HQ's classification: MYLAN — ANDA approval: FERRIC CARBOXYMALTOSE (unspecified) An FDA approval record reflects FDA clearing a specific drug or biologic application for marketing. On 2026-06-25, Argus HQ recorded a FDA approval for MYLAN, rated "info" severity in Argus HQ's classification: MYLAN — ANDA approval: FERRIC CARBOXYMALTOSE (unspecified) An FDA approval record reflects FDA clearing a specific drug or biologic application for marketing. In total, MYLAN has 2 FDA events on file with Argus HQ across the sources Argus HQ currently tracks (FDA Warning Letters, recalls, drug/biologic approvals, and Form 483 inspection observations). Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures. This page reflects only the FDA event types Argus HQ currently tracks -- FDA Warning Letters, recalls, drug and biologic approvals, and Form 483 inspection observations -- and will update automatically as new FDA records are observed. Argus HQ does not independently verify FDA's underlying findings; this page summarizes what FDA has published and links back to the original FDA source for each event. Counting an FDA record here does not by itself indicate an unresolved problem -- warning letters, recalls, and inspection observations are frequently closed out once a firm completes FDA-required corrective action. Investors, physicians, and competitors researching this company can use this page as a single index of every FDA touchpoint Argus HQ has observed, rather than searching FDA's separate warning-letter, recall, and approval databases individually.
Risk pattern analysis
Argus HQ analysis — not an FDA finding
This section is Argus HQ analysis, not an FDA finding. With 2 FDA events on file, there is not yet enough history in Argus HQ's database to describe a multi-event pattern beyond the single category involved. A pattern across multiple FDA touchpoints does not by itself establish that any specific product currently poses a risk; it reflects only the frequency of FDA engagement with this company as recorded in Argus HQ's database. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures. This page reflects only the FDA event types Argus HQ currently tracks -- FDA Warning Letters, recalls, drug and biologic approvals, and Form 483 inspection observations -- and will update automatically as new FDA records are observed.
Frequently asked questions
- How many FDA actions has MYLAN had?
- Argus HQ has recorded 2 FDA events for MYLAN: 0 warning letters, 0 recalls, 2 approvals, and 0 Form 483 inspection observations. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures.
- What is the most recent FDA action against MYLAN?
- The most recent FDA event Argus HQ has on file for MYLAN is dated 2026-06-25, with a severity rating of "info" in Argus HQ's classification. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures.
- Does Argus HQ track new FDA actions for MYLAN automatically?
- Yes. Argus HQ ingests FDA sources daily, including FDA warning letters, recalls, drug and biologic approvals, and Form 483 inspection observations. When a new FDA action linked to MYLAN is observed, this page's event count and history update automatically.
- How many FDA actions does Argus HQ track for MYLAN?
- 2 total: 0 warning letters, 0 recalls, 2 approval records, and 0 Form 483 inspection citations.
Every FDA action tied to this company, the week it happens.
Free weekly briefing. Real-time alerts on paid plans.
Related enforcement actions
Compare with
Two different companies merged onto this page by mistake? Or a name variant missing? Tell us — corrections@argushq.ai
Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder
Cite this record
Reusing this data in reporting or research? Here’s a ready-made citation.
Argus HQ Research (2026). FDA Actions Against MYLAN. Digital Empire LLC. Retrieved from https://argushq.ai/company/mylan
"FDA Actions Against MYLAN." Argus HQ Research, Digital Empire LLC, 2026, argushq.ai/company/mylan.
Argus HQ Research. "FDA Actions Against MYLAN." Digital Empire LLC. Accessed July 13, 2026. https://argushq.ai/company/mylan.
@misc{argushq_argushq_ai_company_mylan_2026,
title = {FDA Actions Against MYLAN},
author = {{Argus HQ Research}},
year = {2026},
publisher = {Digital Empire LLC},
url = {https://argushq.ai/company/mylan},
note = {Accessed: July 13, 2026}
}Source: FDA.gov (aggregated across Warning Letters, Recalls, Approvals, Form 483s) ↗